Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    Welcome !
    My account
    Logout

Progenics Pharmaceuticals, Inc. (PGNX) Stock Forecast 2025 - AI Price Prediction & Analysis

Progenics Pharmaceuticals, Inc. (PGNX) AI Stock Price Forecast & Investment Analysis

Progenics Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading Progenics Pharmaceuticals, Inc. interactive price chart and technical analysis...

Progenics Pharmaceuticals, Inc. (PGNX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Progenics Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Progenics Pharmaceuticals, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Progenics Pharmaceuticals, Inc.: Progenics Pharmaceuticals, Inc. operates in the Health Technology sector, making it an emerging small-cap investment.

Progenics Pharmaceuticals, Inc. (Stock Symbol: PGNX) is a leading company in the Health Technology sector , specifically operating within the Biotechnology industry.

The organization employs approximately 105 professionals worldwide and operates under the strategic leadership of CEO David W. Mims.

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Progenics Pharmaceuticals, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Progenics Pharmaceuticals, Inc.: With $37M in annual revenue and -180.3% net margin, the company demonstrates developing profitability.

Annual Revenue: $37 million generating a -180.3% net profit margin .

Market Capitalization: $353 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -116.9% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Progenics Pharmaceuticals, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Progenics Pharmaceuticals, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Progenics Pharmaceuticals, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Progenics Pharmaceuticals, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Progenics Pharmaceuticals, Inc.: Market positioning analysis based on available financial and operational metrics.

Progenics Pharmaceuticals, Inc. strategically competes in the highly dynamic Biotechnology marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 87.2% gross margin, indicating strong pricing power and operational efficiency.

Progenics Pharmaceuticals, Inc. (PGNX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Progenics Pharmaceuticals, Inc. stock analysis.

Loading Progenics Pharmaceuticals, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Progenics Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Progenics Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Progenics Pharmaceuticals, Inc.: With a P/E ratio of -5.32, the market sees the stock as potentially undervalued.

P/E Ratio -5.32x
P/B Ratio 11.71x
Market Cap $353M
EPS $-0.77
Book Value/Share $0.35
Revenue/Share $0.43
FCF/Share $-0.91
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Progenics Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Progenics Pharmaceuticals, Inc.: An ROE of -116.9% indicates room for improvement in shareholder value creation.

ROE -116.9%
ROA -50.8%
ROIC -59.0%
Gross Margin 87.2%
Operating Margin -173.4%
Net Margin -180.3%
EBT Margin -180.2%
Tax Rate 14.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Progenics Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Progenics Pharmaceuticals, Inc.: A current ratio of 2.12 indicates strong liquidity.

Current Ratio 2.12x
Quick Ratio 1.87x
D/E Ratio 1.47x
Financial Leverage 3.21x
Working Capital $42M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Progenics Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Progenics Pharmaceuticals, Inc.: Free cash flow of $-74M indicates cash challenges that need attention.

Operating Cash Flow $-64M
Free Cash Flow $-74M
Capital Spending $-10M
FCF/Sales -200.5%
CapEx/Sales 27.9%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Progenics Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Progenics Pharmaceuticals, Inc.: An asset turnover of 0.28x suggests room for improvement in asset utilization.

Asset Turnover 0.28x
Receivables Turnover 7.1x
Fixed Assets Turnover 1.6x
Days Sales Outstanding 51 days
Payables Period 132 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Progenics Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Progenics Pharmaceuticals, Inc.: With annual revenue of $37M, Progenics Pharmaceuticals, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $37M
Operating Income $-64M
Net Income $-67M
R&D Expense $128M
SG&A Expense $133M
Cost of Goods Sold $13M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 41%
Cash & Short-term Investments 30%
Total Liabilities 69%
Short-term Debt 7%
Accounts Receivable 6%
Dividend & Shareholder Information
Shares Outstanding 86M

Latest Progenics Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Progenics Pharmaceuticals, Inc. (PGNX) stock price and investment outlook.

, source: Insider Monkey

With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second ...

Progenics Pharmaceuticals, Inc. Competitors & Peer Analysis - Health Technology Sector

Comparative analysis of Progenics Pharmaceuticals, Inc. against industry peers and competitors in the Health Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Progenics Pharmaceuticals, Inc. Stock Forecast

How accurate are Progenics Pharmaceuticals, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for PGNX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Progenics Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Progenics Pharmaceuticals, Inc.'s financial metrics, Health Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Progenics Pharmaceuticals, Inc. a good investment in 2025?

Based on our AI analysis, Progenics Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Progenics Pharmaceuticals, Inc. forecasts updated?

Progenics Pharmaceuticals, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Progenics Pharmaceuticals, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Progenics Pharmaceuticals, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...